vyepti chronic pain drug insight and market forecast

“VYEPTI Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about VYEPTI for chronic pain in the seven major markets. A detailed picture of the VYEPTI for chronic pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the VYEPTI for chronic pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VYEPTI market forecast analysis for chronic pain in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic pain.

Drug Summary

Eptinezumab (ALD-403), sold under the brand name VYEPTI, is a medication for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets CGRP alpha and beta and is administered by IV infusion every 3 months. Eptinezumab-jjmr was approved for use in the US in February 2020.

Eptinezumab, a monoclonal antibody (mAb) administered as a quarterly 30-min IV infusion, was designed for immediate and complete bioavailability with high specificity and strong binding for suppression of CGRP, a neuropeptide believed to play a key role in mediating and initiating migraines, it is the first IV CGRP therapy for migraine prevention.

Mechanism of action

Eptinezumab-jjmr is a humanized monoclonal antibody that binds to the CGRP ligand and blocks its binding to the receptor.

Dosage and administration

The recommended dosage is 100 mg administered by IV infusion every 3 months. Some patients may benefit from a dosage of 300 mg administered by IV infusion every 3 months.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the VYEPTI description, mechanism of action, dosage and administration, research and development activities in chronic pain.
• Elaborated details on VYEPTI regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VYEPTI research and development activities in chronic pain across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VYEPTI.
• The report contains forecasted sales of for chronic pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic pain.
• The report also features the SWOT analysis with analyst views for VYEPTI in chronic pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VYEPTI Analytical Perspective by DelveInsight

In-depth VYEPTI Market Assessment

This report provides a detailed market assessment of VYEPTI for chronic pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

VYEPTI Clinical Assessment

The report provides the clinical trials information of VYEPTI for chronic pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for chronic pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VYEPTI dominance.
• Other emerging products for chronic pain are expected to give tough market competition to VYEPTI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VYEPTI in chronic pain.
• Our in-depth analysis of the forecasted sales data of VYEPTI from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VYEPTI in chronic pain.

Key Questions

• What is the product type, route of administration and mechanism of action of VYEPTI?
• What is the clinical trial status of the study related to VYEPTI in chronic pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VYEPTI development?
• What are the key designations that have been granted to VYEPTI for chronic pain?
• What is the forecasted market scenario of VYEPTI for chronic pain?
• What are the forecasted sales of VYEPTI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to VYEPTI for chronic pain?
• Which are the late-stage emerging therapies under development for the treatment of chronic pain?